Teva Expects To Launch First Biosimilar In Europe By Year End
This article was originally published in The Pink Sheet Daily
Executive Summary
During its second-quarter earnings call, Teva says it is taking steps to launch a G-CSF product in Europe.
You may also be interested in...
G-CSF Biosimilars Approved By EU Could Impact Amgen Sales
Competitors to Amgen’s Neupogen and Neulasta soon could be joined by CT Arzneimittel’s proposed filgrastim product.
G-CSF Biosimilars Approved By EU Could Impact Amgen Sales
Competitors to Amgen’s Neupogen and Neulasta soon could be joined by CT Arzneimittel’s proposed filgrastim product.
Teva/Barr Combination Creates Biosimilar Force
Teva’s $7.46 billion acquisition of Barr will result in a generics powerhouse, expanding U.S. leadership and geographic footprint.